BEGONIA trial: durvalumab plus trastuzumab deruxtecan for HER2-low metastatic breast cancer
In one of oncology's most closely watched experiments, an antibody-drug conjugate paired with an immune checkpoint inhibitor has produced unusually ...
In one of oncology's most closely watched experiments, an antibody-drug conjugate paired with an immune checkpoint inhibitor has produced unusually ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine